

2017 half-year results in line with the Group's expectations

Lyon, September 21st, 2017 – after the market close - **AMOEBA** (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating waterborne bacterial risk and wound care applications, announced today its 2017 half-year results.

The Board of Directors closed the company's consolidated accounts for the 1st half of 2017 at their meeting held on September 21st, 2017.

The statutory auditors conducted a limited audit of the consolidated half-yearly financial statements on June 30th, 2017 and have not identified any significant discrepancies likely to call into question the compliance thereof. They proceeded to the report's signature.

The half-yearly report is currently being issued and will be available on the company's website (www.amoeba-biocide.com) in the coming days.

(In K€)	30/06/2017	30/06/2016
Turnover	75	60
Industrialisation costs	(314)	(456)
R&D costs	(1,401)	(1,022)
Subsidies	278	290
Marketing & Sales	(473)	(454)
General costs	(1,309)	(1,090)
Operational balance	(3,144)	(2,672)
Financial balance	(96)	(16)
Net balance	(3,240)	(2,688)

Half-year results in line with the Group's expectations

The operational balance on June 30th, 2017 was €-3,240 K, in line with the company's forecast.

The analysis of these results indicates:

- A turnover of €75K on June 30th, 2017 mainly made up of the half-yearly licence fee paid by AQUAPROX, amounting to €60 K and the invoicing of industrial R&D tests in Europe for €15 K.
- An increase in research and development costs primarily related to the MA application in Europe and industrial tests in Canada as well as patent fees.

- An increase in general costs reflecting the size of the Group in order to start the industrialization and marketing phase.
- The financial result mainly represents interest fees paid on bank loans (€50 K) partially compensated by financial income on term deposit accounts.

The half yearly net balance is therefore €-3,240 K.

On June 30th, 2017, the Company's shareholders' equity amounted to €15.4 million, compared to €21.8 million on June 30th, 2016. Cash flow is €8.6 million.

First half of the year oriented on business development and the continuation of research and development studies

During the 1st half of 2017, the Company signed 4 new Letters of Intent in Italy, Romania and in the USA prior to entering into a definitive distribution agreement, subject to pending marketing authorizations required in these different territories.

AMOEBBA also signed 2 definitive distribution agreements in the Netherlands and in the USA for the distribution of its BIOMEBA product, pending marketing authorization required in these different territories.

The Company has extended its portfolio of patents in China. It has also obtained the issue in France of a new patent on the biological process against the pathogenic microorganism *Naegleria Fowleri*.

Finally, the Company continued its industrial field tests in Canada and in Europe and finalized research programs within the framework of its regulatory dossier on European marketing authorization.

Recent developments and perspectives

AMOEBBA has continued to expand its commercial network with the signature of a new Letter of Intent with MOMAR Inc prior to entering into a definitive distribution agreement and upon pending the marketing authorisation in the United States.

The Company also signed a definitive distribution agreement with DREWO, subject to pending marketing authorization in Italy.

The company informed about the European working group held on its regulatory dossier (ref: press release of September 11th, 2017).



About AMOEBA:

AMOEBA group's objective is to become the global leader in eliminating waterborne bacterial risk in water treatment and wound care applications. Our solutions represent alternatives to chemical products widely used in the cooling water treatment and the wound care market. In a global market for chemical biocides estimated to be worth EUR 21 bn⁽¹⁾ AMOEBA is focusing on the industrial cooling tower application estimated at EUR 1.7 bn⁽²⁾. Similarly, in a global wound care market estimated at EUR 15.2bn⁽³⁾, AMOEBA is targeting the chronic wound care market in the USA, estimated to be worth EUR 751 million⁽⁴⁾. The use of *Willaertia magna* C2c Maky in health care products will be subject to FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological biocide for water treatment, BIOMEBA, has not yet been granted marketing authorization in the USA, Europe and Canada. AMOEBA is taking the required regulatory steps to be granted marketing authorization in those regions for the use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. More information on www.amoeba-biocide.com.

(1) marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.

(2): Amoéba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

(3) M. Diligence, "Wound Management: An \$18.5 billion+ worldwide market in 2021," MedMarket Diligence, 10 June 2013. [Online]. Available: <http://blog.mediligence.com/2013/06/10/wound-management-an-18-5-billion-worldwide-market-in-2021/>. [Accessed 14 February 2017].

(4) BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017.

Contacts:

AMOEBA

Nathalie COMBROUSSE

Marketing Communication Manager

Tel. : +33 (0)4 81 09 18 15

nathalie.combrousse@amoeba-biocide.com

ACTIFIN

Ghislaine GASPARETTO

Financial Communication

Tel. : +33 (0)1 56 88 11 11

[ggasparetto@actifin.fr](mailto:gasparetto@actifin.fr)